Expanding the Role for Immunotherapy in Triple-Negative Breast Cancer
PD-1 axis blockade, in combination with chemotherapy, improves outcomes in advanced triple-negative breast cancer that is PD-L1 positive. The phase 3 KEYNOTE-522 trial now shows that the addition of pembrolizumab to chemotherapy improves pathological complete response rates regardless of PD-L1 statu...
Gespeichert in:
| Veröffentlicht in: | Cancer cell 2020-05, Vol.37 (5), p.623-624 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 624 |
|---|---|
| container_issue | 5 |
| container_start_page | 623 |
| container_title | Cancer cell |
| container_volume | 37 |
| creator | Savas, Peter Loi, Sherene |
| description | PD-1 axis blockade, in combination with chemotherapy, improves outcomes in advanced triple-negative breast cancer that is PD-L1 positive. The phase 3 KEYNOTE-522 trial now shows that the addition of pembrolizumab to chemotherapy improves pathological complete response rates regardless of PD-L1 status and appears to improve survival.
PD-1 axis blockade, in combination with chemotherapy, improves outcomes in advanced triple-negative breast cancer that is PD-L1 positive. The phase 3 KEYNOTE-522 trial now shows that the addition of pembrolizumab to chemotherapy improves pathological complete response rates regardless of PD-L1 status and appears to improve survival. |
| doi_str_mv | 10.1016/j.ccell.2020.04.007 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2402425482</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1535610820302063</els_id><sourcerecordid>2402425482</sourcerecordid><originalsourceid>FETCH-LOGICAL-c404t-4bd0dfd887594e53d5a93ef20f6f9f0cb79168be86e11f062e0868b70d6b0d3e3</originalsourceid><addsrcrecordid>eNp9kMtu2zAQRYkgRZyk_YICgZbZSB0-RFGLLBLDTQ0YLRAka4IShykNvUrKRvL3pWu3y67mgXvnYg4hnykUFKj8si3aFruuYMCgAFEAVGfkkqpK5VwqeZ76kpe5pKAW5CrGLSQXreoLsuCM11KV5SVZrd4mM1g_vGbzT8yexg4zN4Zs3fe7YUyrYKb3zA_Zc_BTh_l3fDWz32P2ENDEOVuaocXwkXxwpov46VSvycvX1fPyW7758bhe3m_yVoCYc9FYsM4qVZW1wJLb0tQcHQMnXe2gbaqaStWgkkipA8kQVJorsLIBy5Ffk9vj3SmMv3YYZ937eIBgBhx3UTMBTLBSKJak_ChtwxhjQKen4HsT3jUFfeCnt_oPP33gp0HoxC-5bk4Bu6ZH-8_zF1gS3B0FmN7ceww6th4TA-sDtrO2o_9vwG9lTYGB</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2402425482</pqid></control><display><type>article</type><title>Expanding the Role for Immunotherapy in Triple-Negative Breast Cancer</title><source>Cell Press Free Archives</source><source>Elsevier ScienceDirect Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Savas, Peter ; Loi, Sherene</creator><creatorcontrib>Savas, Peter ; Loi, Sherene</creatorcontrib><description>PD-1 axis blockade, in combination with chemotherapy, improves outcomes in advanced triple-negative breast cancer that is PD-L1 positive. The phase 3 KEYNOTE-522 trial now shows that the addition of pembrolizumab to chemotherapy improves pathological complete response rates regardless of PD-L1 status and appears to improve survival.
PD-1 axis blockade, in combination with chemotherapy, improves outcomes in advanced triple-negative breast cancer that is PD-L1 positive. The phase 3 KEYNOTE-522 trial now shows that the addition of pembrolizumab to chemotherapy improves pathological complete response rates regardless of PD-L1 status and appears to improve survival.</description><identifier>ISSN: 1535-6108</identifier><identifier>EISSN: 1878-3686</identifier><identifier>DOI: 10.1016/j.ccell.2020.04.007</identifier><identifier>PMID: 32396855</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><ispartof>Cancer cell, 2020-05, Vol.37 (5), p.623-624</ispartof><rights>2020 Elsevier Inc.</rights><rights>Copyright © 2020 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c404t-4bd0dfd887594e53d5a93ef20f6f9f0cb79168be86e11f062e0868b70d6b0d3e3</citedby><cites>FETCH-LOGICAL-c404t-4bd0dfd887594e53d5a93ef20f6f9f0cb79168be86e11f062e0868b70d6b0d3e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1535610820302063$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32396855$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Savas, Peter</creatorcontrib><creatorcontrib>Loi, Sherene</creatorcontrib><title>Expanding the Role for Immunotherapy in Triple-Negative Breast Cancer</title><title>Cancer cell</title><addtitle>Cancer Cell</addtitle><description>PD-1 axis blockade, in combination with chemotherapy, improves outcomes in advanced triple-negative breast cancer that is PD-L1 positive. The phase 3 KEYNOTE-522 trial now shows that the addition of pembrolizumab to chemotherapy improves pathological complete response rates regardless of PD-L1 status and appears to improve survival.
PD-1 axis blockade, in combination with chemotherapy, improves outcomes in advanced triple-negative breast cancer that is PD-L1 positive. The phase 3 KEYNOTE-522 trial now shows that the addition of pembrolizumab to chemotherapy improves pathological complete response rates regardless of PD-L1 status and appears to improve survival.</description><issn>1535-6108</issn><issn>1878-3686</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp9kMtu2zAQRYkgRZyk_YICgZbZSB0-RFGLLBLDTQ0YLRAka4IShykNvUrKRvL3pWu3y67mgXvnYg4hnykUFKj8si3aFruuYMCgAFEAVGfkkqpK5VwqeZ76kpe5pKAW5CrGLSQXreoLsuCM11KV5SVZrd4mM1g_vGbzT8yexg4zN4Zs3fe7YUyrYKb3zA_Zc_BTh_l3fDWz32P2ENDEOVuaocXwkXxwpov46VSvycvX1fPyW7758bhe3m_yVoCYc9FYsM4qVZW1wJLb0tQcHQMnXe2gbaqaStWgkkipA8kQVJorsLIBy5Ffk9vj3SmMv3YYZ937eIBgBhx3UTMBTLBSKJak_ChtwxhjQKen4HsT3jUFfeCnt_oPP33gp0HoxC-5bk4Bu6ZH-8_zF1gS3B0FmN7ceww6th4TA-sDtrO2o_9vwG9lTYGB</recordid><startdate>20200511</startdate><enddate>20200511</enddate><creator>Savas, Peter</creator><creator>Loi, Sherene</creator><general>Elsevier Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20200511</creationdate><title>Expanding the Role for Immunotherapy in Triple-Negative Breast Cancer</title><author>Savas, Peter ; Loi, Sherene</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c404t-4bd0dfd887594e53d5a93ef20f6f9f0cb79168be86e11f062e0868b70d6b0d3e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Savas, Peter</creatorcontrib><creatorcontrib>Loi, Sherene</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer cell</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Savas, Peter</au><au>Loi, Sherene</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Expanding the Role for Immunotherapy in Triple-Negative Breast Cancer</atitle><jtitle>Cancer cell</jtitle><addtitle>Cancer Cell</addtitle><date>2020-05-11</date><risdate>2020</risdate><volume>37</volume><issue>5</issue><spage>623</spage><epage>624</epage><pages>623-624</pages><issn>1535-6108</issn><eissn>1878-3686</eissn><abstract>PD-1 axis blockade, in combination with chemotherapy, improves outcomes in advanced triple-negative breast cancer that is PD-L1 positive. The phase 3 KEYNOTE-522 trial now shows that the addition of pembrolizumab to chemotherapy improves pathological complete response rates regardless of PD-L1 status and appears to improve survival.
PD-1 axis blockade, in combination with chemotherapy, improves outcomes in advanced triple-negative breast cancer that is PD-L1 positive. The phase 3 KEYNOTE-522 trial now shows that the addition of pembrolizumab to chemotherapy improves pathological complete response rates regardless of PD-L1 status and appears to improve survival.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>32396855</pmid><doi>10.1016/j.ccell.2020.04.007</doi><tpages>2</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1535-6108 |
| ispartof | Cancer cell, 2020-05, Vol.37 (5), p.623-624 |
| issn | 1535-6108 1878-3686 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2402425482 |
| source | Cell Press Free Archives; Elsevier ScienceDirect Journals; EZB-FREE-00999 freely available EZB journals |
| title | Expanding the Role for Immunotherapy in Triple-Negative Breast Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T11%3A02%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Expanding%20the%20Role%20for%20Immunotherapy%20in%20Triple-Negative%20Breast%20Cancer&rft.jtitle=Cancer%20cell&rft.au=Savas,%20Peter&rft.date=2020-05-11&rft.volume=37&rft.issue=5&rft.spage=623&rft.epage=624&rft.pages=623-624&rft.issn=1535-6108&rft.eissn=1878-3686&rft_id=info:doi/10.1016/j.ccell.2020.04.007&rft_dat=%3Cproquest_cross%3E2402425482%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2402425482&rft_id=info:pmid/32396855&rft_els_id=S1535610820302063&rfr_iscdi=true |